Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Biogen Idec
(NQ:
BIIB
)
173.79
-0.21 (-0.12%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Nov 1, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Biogen Idec
< Previous
1
2
3
4
5
6
7
8
9
...
48
49
Next >
Eli Lilly's Alzheimer's Therapy's Broad Label Reflects Regulatory Confidence in Anti-Amyloid Antibodies: Analyst
July 03, 2024
The FDA has approved Eli Lilly's Kisunla (donanemab) for early symptomatic Alzheimer's disease. Kisunla, targeting amyloid plaques, shows a significant reduction in disease progression and may reduce...
Via
Benzinga
Exposures
Product Safety
BIIB STOCKHOLDERS: Lead Plaintiff Deadline Approaching in Biogen Inc. Class Action; Contact Robbins LLP
July 02, 2024
From
Robbins LLP
Via
GlobeNewswire
Eli Lilly Snags Long-Awaited Alzheimer's Drug Approval, Rivaling Biogen, Eisai
July 02, 2024
The company is on deck to rival Biogen and Eisai's Leqembi.
Via
Investor's Business Daily
BIIB Investors Have Opportunity to Lead Biogen Inc. Securities Fraud Lawsuit with the Schall Law Firm
July 02, 2024
From
Schall Law
Via
GlobeNewswire
Forecasting The Future: 19 Analyst Projections For Biogen
June 26, 2024
Via
Benzinga
Biogen Completes Acquisition of Human Immunology Biosciences
July 02, 2024
From
Biogen Inc.
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Biogen, Charge, Fastly, and NIKE and Encourages Investors to Contact the Firm
July 01, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
BIOGEN INC. (NASDAQ: BIIB) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Biogen Inc. Investors of Upcoming Deadline
July 01, 2024
From
Bernstein Liebhard LLP
Via
GlobeNewswire
This Is Massive News for Eli Lilly Investors
June 29, 2024
A panel of advisors to the Food and Drug Administration (FDA) recently recommended Eli Lilly's Alzheimer's candidate.
Via
The Motley Fool
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen
June 28, 2024
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Biogen To Contact Him Directly To Discuss Their Options
From
Faruqi & Faruqi LLP
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Biogen, Charge, Fastly, and NIKE and Encourages Investors to Contact the Firm
June 27, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
“LEQEMBI®” (Lecanemab) for the Treatment of Alzheimer’s Disease Launched in China
June 27, 2024
China is the Third Country to Launch LEQEMBI Following the United States and Japan
From
Biogen Inc.
Via
GlobeNewswire
BIIB Investors Have Opportunity to Lead Biogen Inc. Securities Fraud Lawsuit with the Schall Law Firm
June 25, 2024
From
Schall Law
Via
GlobeNewswire
BIOGEN INC. (NASDAQ: BIIB) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Biogen Inc. Investors of Upcoming Deadline
June 24, 2024
From
Bernstein Liebhard LLP
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Biogen, Charge, and Fastly and Encourages Investors to Contact the Firm
June 23, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Biogen, Charge, and Fastly and Encourages Investors to Contact the Firm
June 19, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
BIIB Investors Have Opportunity to Lead Biogen Inc. Securities Fraud Lawsuit with the Schall Law Firm
June 19, 2024
From
Schall Law
Via
GlobeNewswire
Alzheimer's Drug Stocks: Investing in Eli Lilly, Biogen, Roche
June 19, 2024
The race to develop effective Alzheimer's treatments presents significant opportunities and inherent risks for healthcare investors.
Via
MarketBeat
Exposures
Product Safety
Moderna Stock Soars on Cutting-Edge Personalized Cancer Vaccines
June 17, 2024
Biotechnology firm Moderna Inc. (NASDAQ: MRNA) made mainstream headlines during the pandemic for its COVID-19 vaccines. Moderna is focused on messenger RNA
Via
MarketBeat
Exposures
COVID-19
BIOGEN INC. (NASDAQ: BIIB) INVESTOR ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Biogen Inc.
June 17, 2024
From
Bernstein Liebhard LLP
Via
GlobeNewswire
BIIB INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Biogen, Inc. Investors with Substantial Losses Have Opportunity to Lead Case
June 17, 2024
From
Robbins Geller Rudman
Via
Business Wire
The 3 Best Healthcare Stocks to Buy in June 2024
June 15, 2024
Aging populations and changing lifestyles mean healthcare is a secular story that these best healthcare stocks to buy will capitalize on.
Via
InvestorPlace
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Biogen, Charge, and Fastly and Encourages Investors to Contact the Firm
June 13, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
Kirby McInerney LLP Reminds Biogen, Inc. (BIIB) Investors of Class Action Filing and Encourages Investors to Contact the Firm
June 13, 2024
From
Kirby McInerney LLP
Via
GlobeNewswire
4 Best Stocks to Buy and 3 Best Stocks to Sell: June 2024
June 12, 2024
Consider making moves in these securities, each of which has news that is impacting their share price either positively or negatively.
Via
InvestorPlace
BIIB Investors Have Opportunity to Lead Biogen Inc. Securities Fraud Lawsuit with the Schall Law Firm
June 12, 2024
From
Schall Law
Via
GlobeNewswire
Eli Lilly's Donanemab Gains Favorable FDA Advisory Verdict, Boosting Stock Potential, Says BofA Analyst
June 11, 2024
Eli Lilly's donanemab for Alzheimer's disease garners positive FDA committee verdict, prompting analyst's bullish outlook amid comparisons to Biogen's Leqembi.
Via
Benzinga
Exposures
Product Safety
Eli Lilly Drags Alzheimer's Stocks Prothena, Eisai Lower Despite FDA Win
June 11, 2024
An FDA panel unanimously backed Eli Lilly's Alzheimer's drug, but shares of Lilly and its rivals fell Tuesday.
Via
Investor's Business Daily
Exposures
Product Safety
Global Multiple Sclerosis Drugs Market Size Projected to Reach $38 Billion By 2032 as Demand on R&D for Developing Innovative Drugs Rises
June 11, 2024
EQNX::TICKER_START (NASDAQ:TLSA),(NYSE:LLY),(OTCQX:RHHBY),(NASDAQ:BIIB),(NASDAQ:TGTX) EQNX::TICKER_END
Via
FinancialNewsMedia
Exposures
Product Safety
Global Multiple Sclerosis Drugs Market Size Projected to Reach $38 Billion By 2032 as Demand on R&D for Developing Innovative Drugs Rises
June 11, 2024
From
FN Media Group LLC
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
...
48
49
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.